Literature DB >> 8276178

HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis.

W Z Mehal1, Y M Lo, B P Wordsworth, J M Neuberger, S C Hubscher, K A Fleming, R W Chapman.   

Abstract

BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tree associated with an increase in the HLA alleles DR3, DR52a, DR2, Dw2, and a decrease in DR4. However, it is not certain which of these alleles provides the primary associations. Our aim was to establish the primary HLA associations with PSC and to assess the ability of HLA alleles to mark for disease progression.
METHODS: By applying molecular techniques to archival tissue, we have genotyped 83 PSC patients from two populations and 131 controls for the alleles HLA DR2, DR3, DR4, DRw12, DR52a, and Dw2.
RESULTS: HLA DR3, DR52a, DR2, and Dw2 were all significantly increased in PSC, with the relative risk for DR52a and Dw2 being greater than for DR3 and DR2, respectively. HLA DR4 was significantly decreased, but this may be artifactual to the DR3, DR2 increase. HLA DR4 and not DR52a marks for rapid disease progression in both our PSC populations.
CONCLUSIONS: HLA DR52a and Dw2 are the best candidate alleles for providing the known HLA association with PSC. HLA DR4 and not DR52a marks for rapid disease progression in our two PSC populations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276178     DOI: 10.1016/s0016-5085(94)95085-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis.

Authors:  P C Stokkers; P H Reitsma; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

4.  Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

Authors:  P L Bittencourt; S A Palacios; E L R Cançado; F J Carrilho; G Porta; J Kalil; A C Goldberg
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 5.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 6.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 7.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

8.  Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.

Authors:  S A Mitchell; J Grove; A Spurkland; K M Boberg; K A Fleming; C P Day; E Schrumpf; R W Chapman
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 9.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

10.  An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.

Authors:  D G Forcione; B Sands; K J Isselbacher; A Rustgi; D K Podolsky; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.